Free Trial
NYSEAMERICAN:LCTX

Lineage Cell Therapeutics (LCTX) Stock Price, News & Analysis

Lineage Cell Therapeutics logo
$1.73 0.00 (0.00%)
Closing price 10/8/2025 04:10 PM Eastern
Extended Trading
$1.78 +0.04 (+2.60%)
As of 08:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Lineage Cell Therapeutics Stock (NYSEAMERICAN:LCTX)

Advanced

Key Stats

Today's Range
$1.70
$1.83
50-Day Range
$0.95
$1.79
52-Week Range
$0.37
$1.83
Volume
2.32 million shs
Average Volume
1.85 million shs
Market Capitalization
$395.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.25
Consensus Rating
Buy

Company Overview

Lineage Cell Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
39th Percentile Overall Score

LCTX MarketRank™: 

Lineage Cell Therapeutics scored higher than 39% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lineage Cell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Upside Potential

    Lineage Cell Therapeutics has a consensus price target of $4.25, representing about 145.7% upside from its current price of $1.73.

  • Amount of Analyst Coverage

    Lineage Cell Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Lineage Cell Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Lineage Cell Therapeutics are expected to grow in the coming year, from ($0.12) to ($0.09) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lineage Cell Therapeutics is -9.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lineage Cell Therapeutics is -9.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Lineage Cell Therapeutics has a P/B Ratio of 4.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Lineage Cell Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    12.15% of the outstanding shares of Lineage Cell Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Lineage Cell Therapeutics has a short interest ratio ("days to cover") of 13.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Lineage Cell Therapeutics has recently increased by 2.59%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Lineage Cell Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Lineage Cell Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.15% of the outstanding shares of Lineage Cell Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Lineage Cell Therapeutics has a short interest ratio ("days to cover") of 13.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Lineage Cell Therapeutics has recently increased by 2.59%, indicating that investor sentiment is decreasing.
  • Search Interest

    67 people have searched for LCTX on MarketBeat in the last 30 days. This is an increase of 319% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Lineage Cell Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Lineage Cell Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    26.80% of the stock of Lineage Cell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    62.47% of the stock of Lineage Cell Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Lineage Cell Therapeutics' insider trading history.
Receive LCTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lineage Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LCTX Stock News Headlines

Bitcoin grabs headlines, but smart money likes this token
Bitcoin grabs headlines, but smart money likes this token My research team has identified the token positioned at the absolute center of this incoming capital flood— a project so fundamentally essential to the crypto ecosystem that institutional investors simply cannot ignore it.tc pixel
See More Headlines

LCTX Stock Analysis - Frequently Asked Questions

Lineage Cell Therapeutics' stock was trading at $0.5150 on January 1st, 2025. Since then, LCTX shares have increased by 235.9% and is now trading at $1.73.

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) released its earnings results on Thursday, August, 8th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.01. The company earned $1.41 million during the quarter, compared to the consensus estimate of $1.28 million. Lineage Cell Therapeutics had a negative net margin of 374.84% and a negative trailing twelve-month return on equity of 20.00%.
Read the conference call transcript
.

Shares of LCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lineage Cell Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Moderna (MRNA), JPMorgan Chase & Co. (JPM) and Chevron (CVX).

Company Calendar

Last Earnings
8/08/2024
Today
10/09/2025
Next Earnings (Estimated)
11/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSEAMERICAN:LCTX
CIK
876343
Employees
60
Year Founded
N/A

Price Target and Rating

High Price Target
$9.00
Low Price Target
$2.00
Potential Upside/Downside
+145.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.12)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$18.61 million
Net Margins
-374.84%
Pretax Margin
-373.45%
Return on Equity
-20.00%
Return on Assets
-12.93%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.08
Quick Ratio
4.08

Sales & Book Value

Annual Sales
$9.50 million
Price / Sales
41.59
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.35 per share
Price / Book
4.94

Miscellaneous

Outstanding Shares
228,360,000
Free Float
167,157,000
Market Cap
$395.06 million
Optionable
Not Optionable
Beta
1.77
10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NYSEAMERICAN:LCTX) was last updated on 10/9/2025 by MarketBeat.com Staff
From Our Partners